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Abstract
Introduction: The Third National Alzheimer Plan (2008–2012) was a major public health initiative in France that
included €200 million of funding for research in Alzheimer disease and related disorders (AD). The aim of this study
was to document trends in French academic output in AD following the implementation of the plan.
Methods: Academic output (i.e., number of original articles) and scientific impact (i.e., article citations) of French
research in AD were obtained from the Web of Knowledge core collection database. Analyses compared the 5-year
period immediately before (2004–2008) and after (2009–2013) initiation of the plan. Comparisons were made with
stroke, Parkinson disease, AIDS, and diabetes in the 14 leading countries worldwide and regionally within France.
Results: Worldwide production of original scientific articles between the periods 2004–2008 and 2009–2013 increased by
39 %, and that for AD increased by 46 %. China showed the largest increase and Japan the smallest. The absolute
increase in French output on AD (54.6 %) was larger than that for stroke, Parkinson disease, AIDS, or diabetes. Globally,
France had the third largest relative increase in output in AD (1.7-fold), behind only India (2.5-fold) and China (1.9-fold).
There was a relative 2.3-fold increase in the proportion of French AD articles in the top 1 % globally most cited, larger
than that for French articles on stroke, Parkinson disease, AIDS, or diabetes. At the national level, university hospitals
participated in nearly 50 % of French AD publications. Analyses by geographical area demonstrated marked
heterogeneity. We observed a strong correlation between level of funding and volume of output (R2 = 0.70), but not
between funding and article impact (proportion of top 10 % globally cited articles; correlation R2 = 0.03).
Conclusions: Our study provides evidence of a specific positive impact of the funding provided by the Third National
Alzheimer Plan in nearly doubling the global academic scientific output and increasing by 2.3-fold the top 1 % globally
cited articles of France in AD research. Our bibliometric analyses provide objective and transparent information for policy
makers on the relationship between research funding and academic output.
Introduction
A national public health plan is a politically driven
choice aimed at the mobilization of financial and human
resources to reduce the burden of selected diseases.
Since 2001, France, along with several other countries,
has successively implemented three national plans
against Alzheimer disease and related disorders (AD).
The most recent and comprehensive was the Third
National Alzheimer Plan, driven directly by the presidency
of the French Republic from 2008 to 2013, in which
research was included for the first time as one of the three
major objectives of the plan: “to understand, to cure, to
care” [1]. Funding for AD was shared between research
(€200 million), medical care (€200 million), and medico-
social support (€1.2 billion). The research funding was
allocated by three major bodies: the National Agency for
Research (ANR; under the Ministry of Higher Education
and Research), the Hospital Program for Clinical Research
(PHRC; under the Ministry of Social Affairs and Health),
and the Alzheimer Plan Foundation (created to implement
the overall initiative). Whereas university hospitals (CHUs)
preferentially benefit from PHRC funds, universities in
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partnership with national public research organizations
(RPOs; e.g., Institut National de la Santé et de la Recherche
Médicale (INSERM), Centre National de la Recherche Scien-
tifique (CNRS), Commissariat à l'Energie Atomique (CEA),
and higher education institutions) received funding mainly
through ANR applications. Both research organizations were
eligible for funding from the Alzheimer Plan Foundation.
Given the level of commitment required for a 5-year na-
tional public health plan, it is important to quantify for the
scientists, sponsors, and contributors, in a transparent fash-
ion, the scientific impact of the investment made. It is also
necessary to review the appropriateness of resource alloca-
tion and to provide an objective basis for designing further
research strategies at a regional and national level. With
these objectives, we performed a bibliometric analysis asses-
sing in parallel the impact of the Third National Alzheimer
Plan on both French academic scientific output and the at-
tribution of research funding [2], comparing the 5-year
period immediately before the plan (2004–2008) with the
5 years after initiation of the plan (2009–2013). The relative
contribution of France to the global literature on AD was
assessed in terms of both the quantity (i.e., number of arti-
cles) and quality (i.e., representation in the top 1 % and top
10 % of globally cited publications) relative to four other
major disease areas (stroke, Parkinson disease, HIV, and
diabetes) and benchmarked by international comparisons.
Methods
The Alzheimer Plan Foundation
A non-profit private foundation was created in June 2008 by
the French Ministry of High Education and Research to co-
ordinate and implement the research measures of the Third
National Alzheimer Plan. The Foundation connects multiple
governmental funding sources, such as the ANR and the
PHRC, to support research projects on basic, clinical, or so-
cial research and also plays the part of a think tank to en-
courage public and private financial support. Five major
pharmaceutical companies operating in France (AstraZe-
neca, Merck Sharp & Dohme, Servier, Sanofi, and Ipsen)
provided some financial support as a permanent guarantee.
These private founders were members of the board of direc-
tors but had no input on the scientific options.
Bibliometric analyses
To evaluate the international and national impact of the
Third French Alzheimer Plan, bibliometric analyses were
performed in July 2014 to examine the production of
original scientific articles from France in comparison
with other countries and diseases other than AD. The
analyses compared the 5-year period immediately before
the plan (2004–2008) with the 5 years after initiation of
the plan (2009–2013) and were conducted using the
Thomson Reuters Web of Knowledge core collection
database. All analyses included only full articles in peer-
reviewed journals; other forms of publication were ex-
cluded (i.e., proceedings papers, reviews, abstracts, ob-
ituaries, corrections, editorials).
Research output
Research output was defined as the number of articles
published in journals covered by the Science Citation
Index, the Social Science Citation Index, and the Arts
and Humanities Citation Index in the Web of Science
core collection database.
Comparisons with other countries and major disease areas
Research output was evaluated in AD and related neuro-
degenerative dementias in comparison with four other
major comparator disease areas (stroke, Parkinson dis-
ease, HIV, and diabetes) by use of appropriate search
terms in the topic search. The search included the title,
abstract, keywords, and Thomson Reuters Keywords Plus
fields. AD and related neurodegenerative dementia terms
searchers were “Alzheimer” or “fronto-temporal dementia”
or “semantic dementia” or “posterior cortical atrophy ” or
“progressive aphasia” or “Body Lewy Body disease” or “beta
amyloid” or “amyloid precursor” or “APP and processing” or
“presenilin” or “tau protein.” Articles related to CADASIL,
Parkinson, Creutzfeldt-Jakob, prion, a myotrophic Lateral
Sclerosis, Huntington, multiple sclerosis, Niemann-Pick,
Down syndrome, or Wilson disease were discarded because
they were not supported by the Third National Alzheimer
Plan. As Thomson Reuters KeyWords Plus consist of words
and phrases harvested from the titles of the cited articles
and are embedded in the topic search, we excluded articles
containing the following terms: “epilepsy” or “autism” or
“schizophrenia” or “bipolar glioma” or “carcinoma” or
“stroke” or “cancer” or “child” or “fetal” or “infant” or “new-
born” or “preterm” or “pediatric” or “prenatal” or “neonatal”
or “infant” or “adolescent” or “stroke” or “trauma.”
HIV terms searched were “acquired immune defi-
ciency syndrome” or “HIV.” Diabetes terms searched
were “diabetes” or “diabetic.” The stroke term
searched was “stroke.” For international and national
comparative assessments, country and city informa-
tion was obtained from the author field. Each publica-
tion was counted in full for every institution or
country identified in the author affiliations; that is,
our assumption was that each author, institution, and
country in the listed affiliations made a non-negligible
contribution.
Top 1 % and top 10 % publications
Globally highly cited publications were identified using
Thomson Reuters Essential Science Indicators (ESI)
thresholds, which select the top 1 % or top 10 % of arti-
cles by total citations in each annual cohort from each
of the 22 ESI domains. Each article is assign to 1 of the
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22 scientific domains (and only 1) based on the journal
in which it appears. These indicators allow one to identify
the “essential core” of journal articles within a research
field. The title, abstract, and summary of each article were
manually screened for the top 1 % globally cited articles
for comparison of the top six European Union (EU) coun-
tries and the top 10 % globally cited articles for compari-
son of geographical areas in France.
Output increase
Output increase represents the absolute percentage
increase in the output of publications by a given entity
(i.e., a country or French region) between the periods
2004–2008 and 2009–2013.
Output relative increase
Output relative increase represents the percentage
increase in the output of publications by a given entity
(i.e., a country or French region) between the periods
2004–2008 and 2009–2013, divided by the overall per-
centage increase of the world (for analyses by country)
or France (for analyses by French region) between those
periods.
Relative citation impact
The citation count for each publication attributed to a
field was divided by the mean citations for that field in
the year of publication.
SIGAPS score
The SIGAPS system has been used in France since 2006
to assess the research contribution of all CHUs. It relies
on a classification of the publications into five classes
(A–E) based on the journal impact factor distribution in
each research topic’s category as defined by the Journal
Citation Report Science Edition (JCR 2013 edition). For
each article, the SIGAPS score (from 1 to 32) is calculated
based on the class of the journal in which the article was
published and the position in the author list of the author
affiliated with the CHU. When several researchers of one
CHU coauthor the same article, it is counted once for the
institution with the highest score [3].
Research field assessment
The research fields of articles comprised clinical in-
vestigation (including clinic cohorts), biology (including
clinical chemistry, experimental models, biochemistry,
experimental and cellular pharmacology), neuroimaging,
epidemiology (population cohorts), genetics, and neuro-
pathology. Research fields were allocated based on the
journal (using the Thomson Reuters ESI domains), the art-
icle title, the content of the abstract, and the specialization
of the main authors.
Geographical research areas in France
Twenty-nine geographical research areas were defined
by a specific query using the corresponding French cities
hosting universities and CHUs. The city-based queries
included the suburb cities where affiliated hospitals, uni-
versities, and RPOs are located; for example, the Lyon
research area included Lyon, Pierre-Bénite, Bron, and
Villeurbanne. Analysis focused on the scientific per-
formance of the major French research areas, including
publications from RPOs, higher education institutes,
universities, and CHUs with at least 50 articles dedicated
to AD between 2004 and 2013. CHU output was ob-
tained from the SIGAPS system referencing over 70,000
authors belonging to the 29 CHUs. For Paris, the re-
search area was divided into the 13 Paris universities; for
example, Paris 11 included Orsay, Gif-sur-Yvette, Saclay,
Cachan, Châtenay-Malabry, Bures-sur-Yvettes, Villejuif,
and Bicêtre. As CHUs of Paris are affiliated with Assist-
ance Publique-Hôpitaux de Paris, hospital affiliations
were corrected manually. Each hospital article was at-
tributed to its university; for example, publications from
Hôpital Pitié-Salpêtrière, Hôpital Charles-Foix, Hôpital
Saint-Antoine, Hôpital Tenon, Hôpital Rothschild, and
Hôpital Trousseau-La Roche-Guyon were attributed to
the Paris 06 research area. For high-impact articles (top
10 %), the bibliometric outputs for the French geograph-
ical research areas were also screened manually by au-
thor affiliation. In some specific cases, top 10 % articles
were attributed to specific regional research areas only if
one author was in a leading position (i.e., corresponding
author). Each top 10 % article was attributed to only one
research area.
Results
Allocation of funding in the Third French Alzheimer Plan,
2008–2012
The Third French Alzheimer Plan included a total of
€200 million dedicated to research, of which €45 million
were already engaged through RPOs, €5–7 million for
doctoral positions and staff positions through univer-
sities, €1 million (0.5 %) for the Alzheimer Plan Founda-
tion management and €126 million distributed through
grant applications. The Ministry of Health supported 50
clinical research projects through PHRCs (€24.7 million),
€34.1 million was provided through the ANR, and €41.9
million was distributed through the Alzheimer Plan
Foundation (Additional file 1: Figure S1a).
Grant applications for specific research projects were
reviewed by committees of independent, largely non-
French experts. The quality of the grant applications
assessed by experts was the primary criterion for selection.
There was minimal consideration given to allocation to
specific fields of research, and no geographic targeting.
Similar levels of funding support were allocated to clinical
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investigation (36.5 % of research funds) and to funda-
mental research (24.3 % for biology and 8.2 % for genet-
ics). Almost 20 % of the funds were dedicated to imaging
and technology and more than 10 % to social sciences and
epidemiological studies (Additional file 1: Figure S1b).
Regional funding and scientific output in Alzheimer
disease in France
The impact of the Third French Alzheimer Plan on scien-
tific output was assessed for the major French research
areas (n = 29), including publications from universities,
RPOs, higher education institutes, and CHUs. Production
was assessed in terms of both volume (number of articles)
and impact (proportion of papers in the top 10 % globally
cited and the SIGAPS score for CHUs). For the period
2004–2008, five geographical research areas produced at
least 100 articles related to AD (Paris 06, Toulouse, Paris
11, Lille, and Bordeaux). During the period 2009–2013,
output increased in all geographical research areas and 9
produced at least 100 articles related to AD (Paris 06,
Toulouse, Bordeaux, Montpellier, Paris 11, Lille, Paris 05,
Lyon, and Marseille).
The global quantitative increase in scientific output in
AD (+69.6 %) also appeared to yield an increase in im-
pact, as measured by the number of French articles in
the top 10 % globally cited: For 57.5 % of the top 10 %
cited articles, a French author has a leading position. We
observed an increase of 134 % (from 189 to 442) in the
number of top 10 % articles between the periods 2004–
2008 and 2009–2013. In 2004–2008, 5 research areas led
(corresponding author) more than ten top 10 % articles,
whereas in 2009–2013 a total of 13 research areas led
more than ten top 10 % articles (Table 1). It is noteworthy
that the percentage of top 10 % articles with a correspond-
ing author was above 60 % for the Nice, Caen, and Lille
research areas. The distribution of top 10 % cited articles
by research field did not change markedly between the
two time periods, but there were notable increases in the
number of top 10 % articles in neuroimaging, genetics,
and epidemiology, three fields that received almost 30 %
of French Alzheimer Plan funding.
Figure 1a shows, for the 2009–2013 period, the rela-
tionship between AD scientific output in terms of vol-
ume (number of articles) and impact (proportion of top
10 % globally cited articles, independent of author lead-
ership), as well as the level of funding (size of the bub-
bles) in the major geographical research areas. Overall,
there was a significant correlation (R2 = 0.70) between
the level of financial support and the volume of scientific
output (number of articles), but there was no correlation
(R2 = 0.03) between the level of funding and the impact
of scientific output (proportion of top 10 % articles). The
latter result reflects the observation that several geograph-
ical areas (e.g., Angers. Dijon, Rouen, Caen, and Nice) de-
livered a high proportion of top 10 % cited articles despite
relatively modest levels of funding.
Figure 1b shows the results of the analysis performed
for CHUs using the SIGAPS author’s affiliation. Overall,
the mean contribution of CHUs involved in AD research
was 48 % of French publications. CHU involvement
in AD research was variable within the geographical
research areas. Five of the CHUs contributed to more
than 50 % of the SIGAPS-indexed publications: hospi-
tals in partnership with the University Paris 06, as
well as the CHUs from Toulouse, Bordeaux, Lille, and
Montpellier.
Table 1 Change in the number and proportion of articles in leadership of French research areas between periods 2004–2008 and
2009–2013
2004–2008 top 10 % publications 2009–2013 top 10 % publications Share of funding (%)
Research areas Leadership, n Global top 10 %, n Leadership, % Leadership, n Global top 10 %, n Leadership, % 2009–2013
Nice 2 6 33.3 17 25 68.0 5.2
Caen 13 16 81.3 20 30 66.7 2.1
Lille 10 15 66.7 36 56 64.3 10.6
Toulouse 16 21 76.2 46 80 57.5 6.4
Paris 07 9 13 69.2 12 21 57.1 4.5
Rouen 2 6 33.3 13 24 54.2 3.1
Paris 05 6 8 75.0 13 26 50.0 6.9
Angers 0 2 0.0 11 22 50.0 1.5
Bordeaux 15 24 62.5 23 51 45.1 10.5
Paris 06 23 34 67.6 28 63 44.4 14.1
Paris 11 7 17 41.2 18 46 39.1 3.5
Lyon 5 11 45.5 12 33 36.4 3.6
Montpellier 9 13 69.2 16 53 30.2 4.5
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As with the Web of Science analysis, we observed a
high correlation (R2 = 0.96) between the SIGAPS score
and the volume of scientific output (number of articles)
for CHUs, but there was no correlation (R2 = 0.19) be-
tween the SIGAPS score and the proportion of top 10 %
articles.
Volume of French scientific research output in Alzheimer
disease
To evaluate if the increase of scientific research output
in AD in France was specific and not due to a global
increase in research activity, we compared the change in
scientific output between the periods 2004–2008 and
Fig. 1 Relationship between level of funding received from the Third French Alzheimer Plan, the volume (number of articles/SIGAPS score), and
impact (representation in top 10 % globally cited articles) of Alzheimer disease research in French geographical research areas and university
hospitals (CHUs) in 2009–2013. a Relationship for each geographical research area of the total number of Alzheimer disease articles, the number
of articles in the top 10 % globally cited, and the relative level of funding received from the Third French Alzheimer Plan (size of bubble).
b Relationship for each CHU of the SIGAPS score for Alzheimer disease articles (a measure of research output that takes into account factors
including journal impact factor and the position of the authors within the author list), the number of articles in the top 10 % globally cited, and
the relative level of funding received from the Third French Alzheimer Plan (size of bubble)
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2009–2013 in the most productive countries and com-
pared output in AD with that in stroke, Parkinson dis-
ease, HIV, and diabetes.
Figure 2a shows that global scientific output across all
research fields in the Web of Science database increased
in all countries, with an overall 39 % increase between
the periods 2004–2008 and 2009–2013 (Table 2). The
United States was by far the largest contributor of scien-
tific articles in both periods, but its relative global contri-
bution fell from 30 % to 27 % of total articles, reflecting
the dramatic rise in the number of articles produced
in countries such as China, India, South Korea, and
Australia. France increased its output by 32 % between the
two time periods, but its global share decreased from
5.3 % to 5.0 %. The global share for the United States, the
United Kingdom, and other European countries declined
as well. For AD, global scientific output increased by 46 %
between the periods 2004–2008 and 2009–2013, which
was greater than the increase for Parkinson disease (40 %)
and HIV (32 %) but lower than the output observed for
stroke (55 %) and diabetes (49 %). The absolute increase
in scientific output for AD was higher than the global
mean for China, India, Brazil, South Korea, Australia,
Spain, and France.
Figure 2b shows the relative change in scientific out-
put between the periods 2004–2008 and 2009–2013 in
each disease area in the top 14 countries, correcting for
the overall change in output within each country. The
relative change thus measures the extent to which AD
research has increased compared with research in other
disease areas within each country. France had the third
largest relative increase in scientific output in AD be-
tween the periods 2004–2008 and 2009–2013 (1.7 times
higher than the overall increase in scientific output
across all disease areas), behind only India (2.5) and
China (1.9). In both France and Spain, the relative in-
crease in scientific output in AD was larger than any of
the other four major comparator disease areas.
Fig. 2 Increase in country publication output between the periods 2004–2008 and 2009–2013 for five major disease areas (Alzheimer disease,
stroke, Parkinson disease, HIV, and diabetes) in absolute terms and relative to the overall output within each country. a Percentage increase in the
number of publications overall and in each disease area between the periods 2004–2008 and 2009–2013. The top 14 countries worldwide are
ranked according to their contribution during the period 2004–2008. b For each country, the fold increase in the proportion of publications in
each disease area relative to the overall increase in the number of publications between the periods 2004–2008 and 2009–2013 is shown. The
top 14 countries worldwide are ranked according to their contribution during the period 2004–2008
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Table 2 Number of published articles for the top 14 countries worldwide during the time periods 2004–2008, 2009–2013 and 2004–2013, across all disease areas and specifically
in Alzheimer disease and the four major comparator disease states (stroke, Parkinson disease, HIV and diabetes)
All Alzheimer Stroke Parkinson HIV Diabetes
2004–2013 2004–2008 2009–2013 2004–2008 2009–2013 2004–2008 2009-2013 2004–2008 2009-2013 2004–2008 2009–2013 2004–2008 2009–2013
United States 2,949,083 1,303,555 1,645,528 11,260 14,499 11,561 16,615 6537 8335 20,976 26,938 25,006 33,842
China 1,188,127 383,509 804,618 1247 3830 1289 4370 665 1932 1577 3441 2413 8499
United Kingdom 795,735 343,455 451,080 2487 3435 3241 4689 1767 2214 4080 5461 5822 7752
Germany 757,711 323,922 433,789 2037 2956 2950 4400 1772 2316 1928 2285 4516 6069
Japan 675,315 321,389 353,926 2240 2543 2328 3408 1451 1576 1369 1503 5706 7192
France 537,568 231,875 305,893 1250 1932 1485 2264 997 1281 3123 3331 2890 3726
Canada 467,998 198,202 269,796 1448 1999 1974 3061 992 1354 1963 3014 3227 4889
Italy 424,650 175,930 248,720 1775 2463 1358 2770 1232 1758 2090 2244 3681 5219
Spain 375,748 145,233 230,515 1010 1776 1029 1690 817 1226 1811 2221 2185 3364
India 353,056 134,381 218,675 296 769 319 771 207 534 1201 2122 1512 3487
Australia 334,610 127,767 206,843 822 1512 1172 2199 510 796 1298 2069 2442 4144
South Korea 329,696 117,933 211,763 743 1386 892 2188 432 954 337 509 1588 3702
Netherlands 257,829 104,649 153,180 830 1191 1207 2031 531 814 1106 1675 2137 3285
Brazil 861,367 93,334 168,033 377 753 450 987 270 518 1273 2025 1384 2980















Impact of French scientific research output in Alzheimer
disease
Table 3 shows the relative change in the level (number
of articles) and impact (proportion of articles in top 1 %
globally cited) of French scientific research output in AD
relative to the four major comparator disease areas
between the periods 2004–2008 and 2009–2013. These
results indicate that French scientific output in AD
increased 3.9-fold more than the overall level of French
scientific output between the periods 2004–2008 and
2009–2013, reflecting faster growth in AD research
output than was observed for stroke, Parkinson dis-
ease, HIV, and diabetes. This quantitative rise also
appeared to be reflected in an increase in the relative
impact of articles in AD. There was a 2.3-fold in-
crease between the periods 2004–2008 and 2009–
2013 in the proportion of French AD articles in the
top 1 % globally cited, which was also a greater rise than
that observed for all of the four major comparator
disease areas.
Table 4 shows the output of AD articles, the relative
citation impact, and the number and proportion of arti-
cles represented in the top 1 % cited globally for the six
EU countries that contributed the most between 2004
and 2013. Whereas the United Kingdom and Germany
contributed the greatest number of AD articles during
both 2004–2008 and 2009–2013, the relative citation
impact rose for all six countries, with an increase from
1.3 to 1.9 for France. Similarly, the proportion of top
1 % articles increased for all countries, including France
(from 1.7 % to 2.4 %). Further analysis of the top 1 %
articles showed that the predominant field of research in
AD varied among countries. The proportion of articles on
clinical investigation was >30 % in the United Kingdom,
the Netherlands, Spain, and Italy and approximately 20 %
in France and Germany. Compared with the other EU
countries, French articles in AD showed a greater
representation of research in epidemiology, genetics,
and imaging.
Discussion
Our results show an overall acceleration following the
Third French Alzheimer Plan of the academic scientific
output of France in AD research in terms of both vol-
ume and impact. Bibliometric analysis enabled assess-
ment of the scientific impact of the plan on different
geographical areas within France. The results show that
six research areas contributed to almost 50 % of French
AD articles. A positive correlation was observed between
the level of financial support and global scientific contri-
bution of the different geographical areas, although no
correlation was detected between level of funding and
article quality and/or impact. The increase in French AD
research output was higher than for the four comparator
disease areas and was the highest among other major
European countries. Taken together, our bibliometric
results show a specific impact of the Third French
Alzheimer Plan.
Although the results of bibliometric approaches must
be interpreted with caution and due consideration, given
their limitations [4–6], the main points for discussion
from our study are not a bibliometric ranking of re-
search between different countries or different French
geographical research areas per se, but the answer to
two major questions: (1) Did the funding of a national
Alzheimer plan expand academic research on AD and
related dementias (if yes, where and by how much)? (2)
What conclusions can be drawn for future consideration
when this evidence is made public to encourage and in-
crease the productivity of academic research (in which
specific fields and by which collaborations)?
Despite the context of a global proliferation of scien-
tific publications, which reflects as much an increase in
production as it does many changes in editorial policies
and pressures to publish, our study leaves no doubt that
the French research contribution to AD increased con-
siderably between the periods 2004–2008 and 2009–
2013 in terms of both volume (number of articles) and
impact (assessed by the relative representation of articles
Table 3 Change in the impact of French Alzheimer disease research between the periods 2004–2008 and 2009–2013, as assessed
by research output and representation in the top 1 % globally cited articles compared with French scientific output in stroke,
Parkinson disease, HIV, and diabetes
Research output
(% France’s share of output)
Output relative increase
(fold change)
France’s share of top 1 % globally
cited articles
Top 1 % relative increase
(fold change)
2004–2008 2009–2013 2004–2008 2009–2013
Alzheimer disease 1, 082 (0.4 %) 1, 836 (0.6 %) 3.9 18 (0.7 %) 44 (1.1 %) 2.3
Diabetes 2, 890 (1.1 %) 3, 725 (1.2 %) 1.6 75 (3.0 %) 130 (3.2 %) 1.2
HIV 3, 092 (1.1 %) 3, 297 (1.0 %) 0.4 43 (1.7 %) 58 (1.4 %) 0.6
Parkinson disease 997 (0.4 %) 1, 281 (0.4 %) 1.6 17 (0.7 %) 21 (0.5 %) 0.4
Stroke 1, 495 (0.5 %) 2, 264 (0.7 %) 2.9 46 (1.8 %) 98 (2.0 %) 1.8
Overall 270, 314 318, 946 1 2, 496 4, 041 1
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in the top 1 % globally cited). French scientific output in
AD increased more in quantity and quality by compari-
son to several major countries and, within the country
itself, by comparison with research productivity in other
fields, such as Parkinson disease, HIV, and diabetes. It is
noteworthy that with stroke, a field supported by a spe-
cific plan (2010–2014) [7], the difference is less marked.
Our study showed that, at the national level, the CHUs
are major players in French research, participating in
48 % of French AD publications. Almost all CHUs
increased their output after the Third French Alzheimer
Plan, improving both their SIGAPS score (based on jour-
nal impact factor and author position) and their propor-
tion of top 10 % globally cited publications (with or
without leadership position). Analyses by geographical
area demonstrated notable heterogeneity at a regional
level, with the majority of the scientific output coming
from six areas. Whereas some of these contained centers
that are well established in AD research, two small,
focused research areas emerged as a result of the plan. We
compared the percentage of top 10 % cited publications,
rather than the number of top 10 % publications (which is
related to the number of researchers), as a measure of
impact. Whereas during the 2004–2008 period only four
research areas had more than 20 % of their articles in
the top 10 % most cited (Caen, Paris 06, Paris 07, and
Bordeaux), after the plan 16 research areas reached that
level and 4 were above 30 % (Angers, Toulouse, Rouen,
and Dijon). It is noteworthy that all fields of biomedical
research are not equally developed in all geographical re-
search areas, and public knowledge about the diversity of
the strongest points of each site may encourage collabora-
tions in large-scale projects at a national level.
Our juxtaposition of the level of funding and production
of original articles should be interpreted with caution.
First, a public health plan is more than a financing issue.
Through governmental support, such a plan should gener-
ate a nationwide mobilization to engage a range of stake-
holders across scientific, medical, and social networks
(e.g., the National Center for Ethics, France Alzheimer,
and the Médéric Alzheimer Foundation). Fifty universities
offered young researchers, pharmacists, and physicians
2-year hospital positions and a 1-year training grant
on drug development, which led to recruitment of a total
of 72 health professionals. The Third French Alzheimer
Plan also mobilized broader activities across the EU at the
time of French presidency in 2008. A bibliometric analysis
focusing on scientific literature cannot measure the wider
societal impact of such an investment, in France and in
the EU in terms of raising awareness of AD. Second, there
is a significant lag time between funding allocation and
the publication of scientific articles. Although our review
considered a 5-year time period after initiation of the plan,
this may not be sufficient for areas such as clinical re-
search, where there are significant administrative and eth-
ical issues to be addressed in implementing new projects.
Indeed, the choice was made in France not to create a
new institute or agency similar to what was done for can-
cer and HIV research. Instead, with a very small adminis-
trative structure, the Third French Alzheimer Plan rapidly
delivered support for previously productive areas of
research (e.g., epidemiology and genetics) within 2 years.
More comprehensive infrastructure projects, such as the
Memento Cohort and the Acquisition Center and Image
Processing, were then initiated, but they will deliver re-
sults over a longer time frame than 5 years.
With these caveats in mind, analysis of the correlation
between level of funding and scientific output across
French geographical research areas yielded some inter-
esting results. Whereas there was a strong correlation
between funding and the volume of scientific output, no
such correlation was observed between funding and
article impact (proportion of top 10 % articles). It may
therefore be more appropriate for future allocation of re-
search funding to take into account bibliometric analyses
such as ours that assess the impact of a group’s research
in addition to the volume of their output. Along similar
lines for CHUs, the strong correlation observed between
SIGAPS score and volume of scientific output was ex-
pected. The lack of correlation between SIGAPS score
Table 4 Relative impact of French Alzheimer disease research between the periods 2004–2008 and 2009–2013, as assessed by























France 1082 1.34 18 1.66 1836 1.92 44 2.40
Germany 1596 1.56 25 1.57 2316 2.16 65 2.81
Italy 1274 1.38 13 1.02 1797 1.67 30 1.67
Netherlands 720 1.78 17 2.36 1087 2.72 28 2.58
Spain 1001 1.02 4 0.40 1884 1.76 22 1.17
United Kingdom 1681 1.66 43 2.56 2294 2.59 81 3.53
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and the proportion of top 10 % cited articles strengthens
arguments that assessments of research groups must
take into account both the impact factor of target jour-
nals and publication citations to draw appropriate con-
clusions on performance. There may be multiple reasons
for the observed lack of correlation between funding and
article impact; for example, some areas of research were
of greater current interest and were therefore more likely
to attract more citations during the period of evaluation
(e.g., neuroimaging in the Caen area). Similarly, some
research projects are more internationalized and may
therefore attract more citations (e.g., clinical investigations
in Toulouse). Some geographical research areas are likely
to have benefited from other, international sources of
funding to conduct high-impact research and could there-
fore have generated publications with a scientific output
apparently uncorrelated with the level of funding from the
Third French Alzheimer Plan.
At the global level, the United States is the leading
country for scientific research. It produced almost 26,000
articles in AD (approximately 40 % of global output in the
field) during the period 2004–2013. The majority of fund-
ing for AD research in the United States comes from the
federal government via the National Institute on Aging
(NIA), and, since 1985, AD Centers and AD research
Centers have been established in major medical schools.
In France, by contrast, university memory centers for re-
search and appeal were only established in 2002, and only
during the Third French Alzheimer Plan were these ex-
tended nationwide. Despite the 2008 financial crisis, major
investments in Alzheimer research were announced by
several countries in Europe (notably the United Kingdom
and Germany) and, later on, by the United States. Accord-
ing to our analysis, the United Kingdom and Germany
remain major contributors in AD, ahead of France. Several
other countries also contributed in quantity and quality to
worldwide academic output, in some cases (Australia, the
Netherlands, and Germany) as a result of national AD/de-
mentia plans. There are as yet no national dementia plans
in other countries, such as China, India, and South Korea
[8–11], but these countries face a major demographic
challenge in terms of the age profile of their populations,
and it is notable that they have dramatically accelerated
their research in AD and other disease areas. Following
this first attempt to identify an association between a na-
tional investment in research on a disease and the level of
scientific output, it would now be useful to investigate in
these other countries (1) the final grant attributions by
comparison with the initial political announcements and
(2) the evolution in each country’s global scientific output.
An international working group on this issue would be
helpful to improve and standardize methodology for the
selected indices and address the delays of follow-up be-
tween grant attribution and publication of original articles.
Conclusions
Our study provides evidence of the probable impact of a
national effort in France to stimulate improved diagnosis
and treatment of AD and dementia, which focused on
original research as far as possible in the economic con-
text. We believe that bibliometric assessment and ana-
lysis, whatever its limits, should be mandatory at a time
when many countries have launched specific initiatives
to promote research in AD and dementia (exemplified
by the recent Global Action Against Dementia summit).
Given that a minimum 5-year interval is essential to en-
suring a sufficient production of original articles and to
measure their impact, we advocate a continuous process
for bibliometric assessment rather than a one-time,
snapshot approach. Such an approach would contribute
to better orientation of scientific policies within and be-
tween countries and encourage national and international
collaborations around the most productive sites in certain
fields of research, rather than using bibliometric analysis
primarily as a tool to benchmark universities or countries.
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Additional file 1: Figure showing the distribution of the funding of
the French Alzheimer Plan and the distribution by research field.
Figure S1. a Research funding of the French Alzheimer Plan by program.
aGenome-wide association study (GWAS): an ongoing program of genetic
research based on previously collected and documented DNA samples.
bThree Cities (3C) Study: a population cohort research study. cNational
Platform for Image Acquisition and Processing (CATI): a nationwide
infrastructure program. dA Methodological Research Group to manage a
new cohort of 2300 patients in the prodromal stage of Alzheimer disease
attending university memory clinics (the Memento Cohort): a nationwide
infrastructure program. eIncluded 50 supplementary hospital positions for
2 years, competitively allocated to young scientists, pharmacists, and
physicians, and a 1-year training program on international development
of Alzheimer drugs, which attracted 72 young and senior health
professionals. fCenter for Early Onset Alzheimer Disease (CNRMAJ):
establishment of a network around Rouen, Lille, and Paris to recruit 225
families fulfilling the criteria of early-onset dementia (before age 65 years)
and one confirmed case of Alzheimer disease in the family. gNational
Data Bank for Alzheimer Disease patients (Nice CM2R): creation of a
program to collect standardized online information nationwide from all
patients referred to memory clinics or university memory clinics from
2009 onward. In 2012 and 2013, a total of 177,242 new patients were
added to the National Data Bank. b Research funding of the French
Alzheimer Plan by program and by research field. Field of research was
defined according to the title and abstract of the grant proposals. The
Ministry of Health supported 50 projects of clinical research through
Hospital Programs for Clinical Research (PHRCs). Public research
organizations (RPO) supported by the French National Research
Agency (ANR) and the Alzheimer Plan Foundation. CHU, university
hospitals. (PDF 214 kb)
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